Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Polypharmacy in schizophrenia

Research output: Contribution to journalReviewResearchpeer-review


  1. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Benzodiazepines and antipsychotics in severe mental illness

    Research output: Book/ReportDoctoral thesisResearch

  2. Association between global functioning at first schizophrenia diagnosis and treatment resistance

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom profile which comprises a clinical platform for widespread use of polypharmacy even though antipsychotic monotherapy is the recommended treatment regimen. This narrative review provides a summary of the current gap between evidence and practice for use of antipsychotic combination therapy in patients with schizophrenia. Antipsychotic polypharmacy is frequently prescribed instead of following international consensus of clozapine monotherapy in treatment-resistant patients. Antipsychotic-benzodiazepine combination therapy clearly has a role in the treatment of acute agitation whereas there is no evidence to support an effect on core schizophrenia symptoms when chronically prescribed. Antidepressants are typically added to antipsychotic treatment in case of persistent negative symptoms. Available evidence suggests that antidepressants may improve negative symptom control in schizophrenia. Combining an antipsychotic with an antiepileptic is not supported by any firm evidence, but individual mood stabilizers have come out positively in single trials. Generally, the evidence base for polypharmacy in schizophrenia maintenance treatment is sparse but may be warranted in certain clinical situations. Therapeutic benefits and side effects should be carefully monitored and considered to ensure a beneficial risk-benefit ratio if prescribing polypharmacy for specific clinical indications.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Publication statusE-pub ahead of print - 6 Jan 2020

ID: 59086833